Lutetium-177 DOTATATE: A Practical Review

Pract Radiat Oncol. 2022 Jul-Aug;12(4):305-311. doi: 10.1016/j.prro.2022.02.002.


Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that originate in endocrine tissues throughout the body. Though most are indolent, clinical outcomes vary greatly based on histologic differentiation and grade. Peptide receptor radionuclide therapy has emerged as a promising treatment for patients with locally advanced and/or metastatic disease refractory to standard of care treatment. The phase III NETTER-1 trial found that [177Lu] Lu-DOTA-[Tyr3]-octreotate improved disease-free survival versus octreotide alone for somatostatin receptor-positive gastroenteropancreatic NETs and had a favorable toxicity profile, leading to Food and Drug Administration approval. [177Lu] Lu-DOTA-[Tyr3]-octreotate is an important new treatment that expands the role of radiation in the treatment of NETs. Several important trials are ongoing to better elucidate the role of this treatment.

Publication types

  • Review

MeSH terms

  • Humans
  • Lutetium* / adverse effects
  • Neuroendocrine Tumors* / radiotherapy
  • Octreotide / adverse effects
  • Positron-Emission Tomography
  • Radioisotopes* / adverse effects
  • Radionuclide Imaging
  • Radiopharmaceuticals / adverse effects


  • Radioisotopes
  • Radiopharmaceuticals
  • copper dotatate CU-64
  • Lutetium
  • Lutetium-177
  • Octreotide